MorphImmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company's proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases efficacy of known effector molecules, ultimately improving outcomes for patients.
Location: United States, Indiana, West Lafayette
Employees: 1-10
Total raised: $17.1M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 08.11.2023 | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.02.2022 | - | $17.1M | - |
Mentions in press and media 2
| Date | Title | Description |
| 03.07.2023 | Startup led by former Seagen CEO Clay Siegall merges with public company in $125M deal | Clay Siegall. (Seagen Photo) Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in a deal boosted with $125 million from private investors. Siegall will serve as CEO, pr... |
| - | MorphImmune | “MorphImmune | Home” |